Mutations in the androgen receptor gene in 46,XY individuals can be associated with the androgen insensitivity syndrome, of which the phenotype can vary from a fem ale phenotype to an undervirilized or infertile m ale phenotype. We have studied the androgen receptor gene of androgen insensitivity patients to get information about amino acid residues or regions involved in D NA binding and transcription activation. Genomic DNA was analysed by PC R -SSC P under two different conditions. Three new mutations were found in exon 1 o f three patients with a fem ale phenotype. A cytosine insertion at codon 42 resulted in a frameshift and consequently in the introduction o f a prem ature stop at codon 171. Deletion of an adenine at codon 263 gave rise to a prem ature stop at codon 292. In both these cases, receptor protein was not detectable and horm one binding was not m easurable. In a third patient, a guanine-to-adenine transition at codon 493 converted a tryptophan codon into a stop codon. Genital skin fibroblasts from this patient were not available. In exon 2 o f the androgen receptor gene of a patient with receptor-positive androgen insensitivity, a cytosine-to-adenine transition, converting alanine 564 into an aspartic acid residue, resulted in defective DNA binding and transactivation. In three other receptor-positive androgen insensitivity patients no m utations were found with PCR-SSCP.
INTRODUCTION
Androgens play a major role in male sexual differen tiation and development. The actions of androgens are exerted through the androgen receptor (AR) which modulates transcription of androgen-responsive genes. The AR belongs to a super-family of receptors for steroid hormones, thyroid hormones and retinoids. Characteristic for the members of this family are the distinct functional domains; the N-terminal domain involved in transcription regulation, a D N A binding domain, composed of two zinc fingers, a hinge region and the C terminal ligand binding domain [1 ] . Mutations in the AR in 46,XY individuals are associated with the androgen insensitivity syndrome (AIS), a disorder with a wide spectrum of phenotypes. Subjects with complete AIS exhibit a female phenotype, whereas other AIS subjects show a phenotype with ambiguous genitalia, called partial AIS. The majority of the mutations reported up to now are point mutations, located in the ligand binding domain [2 , 3] . AIS subjects with an AR of normal molecular mass and no abnormalities in ligand binding are an interesting group, because they may provide information about essential amino acid residues or regions, directly involved in transcription activation, Deletion mapping revealed that almost the entire N-terminal domain is necessary for full AR receptor transactivating activity [4] . Therefore, AR mutations interfering with correct receptor functioning may be expected in this domain. However, except for the expanded glutamine stretch, associated with Kennedy's disease, only six mutations in exon 1 of the ARhave been reported [5] [6] [7] [8] [9] [10] . Five of these resulted either directly or indirectly in the introduction o f a premature stop codon.
In this study we describe three new exon 1 mutations, all resulting in the introduction of premature stop codons. Zoppi et a l [10] reported a patient in which a single nucleotide substitution resulted in a premature stop at codon 60. Synthesis of AR protein was found to be initiated downstream of the termination codon. Therefore, we have investigated whether truncated AR forms were present in genital skin fibroblasts of the patients with an exon 1 mutation. A new mutation was also detected in the first zinc finger of the D N A binding domain of a patient with receptor-positive AIS. N o exon 1 mutations, resulting in receptor-positive AIS, were found. In three other patients with receptorpositive AIS3 no mutation was detected by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis.
MATERIALS AND M ETH O DS

Clinical subjects
Subject A: 46,XY index patient with complete AIS was admitted at the age of 1 yr because of a bilaterally inguinal hernia. She has a younger 46,XY sister with the same phenotype. Subject B: 46,XY patient, diagnosed as having complete AIS. The sister of the patient's mother was known with primary amenorrhea. Subject C: 46,XY patient, with a complete female phenotype and from a family with more affected members.
Subject D: 46,XY patient who was diagnosed as having complete AIS at birth in the absence of a positive family history. She came to medical attention because of suspected dysmorphology. After further clinical examination the diagnosis of AIS was made.
Subjects without a mutation: All patients displayed a 46,XY chromosome pattern, had no mullerian duct remnants and male hormonal levels were present in the serum. Two of them have the typical phenotype of complete AIS and one case has a phenotype with ambiguous genitalia.
The phenotype and the AR gene mutation of each subject are summarized in Table 1 . 
Table L Summary of phenotypes and AR gene mutations of index subjects
M utation detection
Genomic D N A , isolated from blood lymphocytes, was screened by PCR-SSCP. Seventeen primer sets for overlapping fragments were used to amplify the coding region and the exon flanking intronic regions of the hAR. A 15 pi PCR reaction mixture was used, containing 100 ng genomic D N A , 70 ng of each oligonucleotide, 40 jaM of each dNTP, 10 mM Tris HCl ( p H 9.0), 1.5 mM MgCl2, 5 mM KC1, 10% DMSO (in case of amplifying exon 1), 1.0 jj.Ci [a 32P] dATP (Amersham, Little Chalfont, Bucks., U.K.) and 0.1 unit Supertaq DNA polymerase (HT Biotechnology Ltd, Sphaero Q, Leiden, The Netherlands). For PCR fragments covering the glycine stretch, 50% deaza dGTP was used with 50% dGTP. Reactions were denatured at 95°C and subjected to 30 cycles of dénaturation at 95°C for 1 min, annealing for 2 min at different temperatures ( Table 2 ) and elongation at 72°C for 1 min. In Table 2 oligonucleotides used for PCR amplification of the human AR gene and for direct sequencing are indicated. Samples consisting of 1 jil of PCR product and 9 |J sample buffer (95% formamide, 5% glycerol, 20 mM EDTA, 0.02% bromophenoi blue and 0.02% xylene cyanol FF) were denatured before loading onto a gel containing 7% acrylamide, 1 X TBE buffer (Tris-borate, pH 8 
Cell culture conditions
Genital skin fibroblasts were cultured in Modified Eagle's medium (MEM, containing 10 % fetal calf serum, minimal essential amino acids (Gibco, Life Technologies, Breda, The Netherlands) and antibiotics at 37°C and 5% C 0 2. Fibroblasts were grown to confluency, washed two times with PBS-buffer and cytosols or whole cell lysates were prepared.
Preparation of whole cell lysates
Genital skin fibroblasts were grown to confluency and scraped in 1 ml lysis-buffer (40 mM Tris, 1 m M EDTA Table 2 . Sequence o f oligonucleotides used fo r P C R -S S C P screen in g o f th e h u m a n A R g e n e Oligo Location PCR fragment Annealing temperature (°C) Sequence
-7 0 A 5 -U T R j exon 1 Exon 1 A* 55 G C C T G T T G A A C T C T T C T G A G C 95B Exon 1 C T T G G G G A G A A C C A TC C TC A 35A Exon 1 Exon 1 B 58 T c C G C G A A G T G A T C C AGAAC 95B Exon 1 C T T G G G G A G A A C C A TC C TC A 80A Exon 1 Exon 1 C 64 AGCAAGAGACTAG CCCCAGG CAGC 172B Exon 1 C G G A G C A G C TG C TTA A G C CGGGG 160A
Exon 1 Exon 1 D
G C T G C C C C A T C C A C G T T G T C C C T G C T 250B Exon 1 A C TC A G A TG C TC C A A C G C C TC C A C 240A Exon 1 Exon 1 E T G T G T A A G G C A G T G T C G G T G T C C A T 320B Exon 1 C G C C T T C T A G aC C T T T G G T G T A A C 305A Exon 1 Exon 1 F 64 CAGGCAAGAGCACTGAAGATACTGC 385B Exon 1 G G T T C T C C A G C T T G A T G C G A G C G T G 361A Exon 1 Exon 1 G 58 C G C G A C TA C TA C A A C TTTC C A C TG G 445B Exon 1 C A C A C G G TC C A TA C A A C TG 1A Exon 1 Exon 1 H 55 T C C T G G C AC A C T C T C TTC AC 490B Exon 1 G C C A G G G TA CC A C A C A TC A G G T 47 0A Exon 1 Exon 1 I 57 G T A G C C C C C T A C G G C T A C A IB Intron 1 CAG AACACAG AG TG ACTCTG C 2A Intron 1 Exon 2 55 G T C A T T T A T G C C T G C A G G T T 2B Intron 2 T C T C T C T C T G G A A G G T A A A G 3A Intron 2 Exon 3 55 T C A G G T CTAT C A A C T CTTG 3B Intron 3 G G AG AGAGG AAG G AGG AG G A 4A Intron 3 Exon 4 A 55 A T T C A A G T C T C T C T T C CTTC 14NB Exon 4 T G C A A A G G A G T tG G G C T G G T T G 4AA Exon 4 Exon 4 B 55 CAG AAG CTtACAG TG TCACACA 4B Intron 4 G C G T TC A C TA A A T A TG A T C C 5A Intron 4 Exon 5 55 G A C TC A G A C TTA G C TC A A C C 5B Intron 5 A TG A C C A C C A A C C A G G TC TG
6A
Intron 5 Exon 6 55 C A A TC A G A G A C A TTC C TC TG G 6B
Intron 6 A G T G G T C C T C T C T G A A T C T C 7A
Intron 6 Exon 7 
T G C T C C T T C G T G G G C A T G C T 7B Intron 7 T G G C T C T A T C A G G C T G T T C T C
8LA
Intron 7 Exon 8 55 A G G C C AC CTC C T T G T C AAC
Preparation of cytosols
Cells were scraped in 1 ml cytosol-buffer (40 m M Tris, 1 mM EDTA pH 7.4, 10 % glycerol, 10 m M D T T , 10 mM molybdate, and freshly added: 600 fiM phenylmethylsulfonyl fluoride, 500 |tM bacitracin and 500 mM leupeptin), and homogenized with a teflon potter. The derived cell homogenates were centrifuged for 10 min at 100,000 x^, and the supernatants stored at -8 0°C until use.
Characterization of the A R protein by S D S -P A G E and immuno staining
The AR protein was immunoprecipitated from genital skin fibroblast lysates, with monoclonal antibody F 3 9 .4 .1., as described before [11] . After electrophoresis on a 7% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SD S-PA G E) gel, the proteins were transferred to nitrocellulose and immunostained with polyclonal antibody, Sp061. After washing, the membrane was incubated with a second, peroxidase coupled antibody, to visualize the protein.
S c a tc h a rd an a lysis
For studying the binding characteristics two different assays were used: either a binding assay in which genital skin fibroblast cytosols were used, or a whole cell assay. Cytosols were incubated overnight at 4°C with increasing concentrations (0 -0 .1 -0 . After protamine precipitation to remove the free steroid, specifically bound 3H-R1881 was measured. T he total amount of protein was assayed according to the method o f Bradford [12 ] .
Genital skin fibroblasts were incubated with increas ing concentrations of 3H-R1881 (0 .02, 0.05, 0.3, 1.0,  3.0 nM ) to obtain a saturation state. The non-specific 572 H. T. Brüggenwirth et a l binding was determined after incubation with a 100-fold molar excess of non-radio active steroid. After a 1 -h incubation period at 37°C, cells were washed four times with ice-cold 20 nM Tris, 0,15 mM NaCl, pH 7.4. The cells were scraped in 1 ml lysis-buffer (TEG pH 7.4: 20 mM Tris* 15 mM EDTA, 10% v/v glycerol, 600 jxM phenylmethylsulfonyl fluoride and 500 jiM bacitracine). After 10 min centrifugation at 800 x g the pellet was lysed by adding 1 ml 0,5 N NaOH and a 30 min incubation at 56°C. Scintillation cocktail (5 ml Clumin (Packard, Tilburg, The Nether lands)) was added to 500 j.il of each sample and 3H-activity was measured in a scintillation counter. The amount of protein was quantified by the method of Bradford [12] . Scatchard analysis was carried out to determine the dissociation constant (K d) and the number of binding sites (B,uax) . a codon 171 (Fig. 2) . In a second complete AIS subject premature stop codon were detected in the hAR of three (B) a deletion of an adenine at codon 263 of the AR complete AIS patients (Fig. 1) . In one receptor-positive gene gave rise to a stop codon at position 292 (Fig. 2) , patient a mutation was found in exon 2 (Fig. 1 ) . In three other patients, diagnosed as also having a receptor-positive form of AIS, no aberrant PCR-SSCP pattern was detected.
RESULTS
The coding part of the hAR gene was screened by amplification of genomic D N A with a set of 18 primer pairs, followed by SSCP analysis, performed under two different conditions. In case of an aberrant PCR-SSCP profile, direct sequencing was performed. Three new frameshift and consequently in a premature stop at exon 1 mutations, all resulting in the introduction of
Sequence analysis indicated a cytosine insertion at codon 42 of the AR gene of patient A, resulting in a E x o n 1 E xon 1 E xon 1 E xon 2 A D G A guanine-to-adenine transition at codon 493 changed a tryptophan codon (TGG) into a stop codon (TGA)
in the AR gene of patient C (Fig. 2) . A Kpn I restriction site, which is a unique site in AR cDNA, was destroyed by the mutation and is informative with respect to carrier detection. Fig. 2) . In case frame shift and the introduction o f a premature stop at of patient A no AR protein of 87 kDa could be detected codon 412. Downstream of this premature stop codon (Fig. 3, lane 2) (Fig. 3, lane 3) . Furthermore ligand in which a cytosine-to-thymine transition, converting binding studies were negative. Genital skin fibroblasts a glutamine (CAG) residue at position 60 in the were not available from patient C.
We stern-immun ob lotting was performed to investi gate if a truncated AR form was expressed in genital skin fibroblasts of subjects A and B. Truncated forms might result from internal reinitiation of translation,
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. This corresponds with the observation three A U G s are located, in frame with the premature that ligand binding was not measurable in cytosols, termination codon, A low level o f high affinity binding prepared from genital skin fibroblasts of patient A. The to androgens and also to D N
A new mutation was found in exon 2, which encodes the first zinc finger of the D N A binding domain of the polymorphic glutamine stretch, into a premature stop (TAG ). In vitro experiments suggested that internal initiation occurs from the first in-frame A U G codon at AR. A transition of cytosine to adenine converts an position 188, resulting in a 87 kDa protein. In genital alanine residue at position 564 into an aspartic acid skin fibroblasts, a low but detectable level of specific residue (position depicted in Fig. 4 ). This mutation androgen binding with an accelerated dissociation rate resulted in defective D N A binding and transactivation, and will be described in more detail elsewhere. was measured. In patient A, the premature stop codon was present at codon 171. A shortened protein o f In two of the patients, diagnosed as having complete approximately 87 kDa, however, could not be detected AIS, and in one patient with partial AIS, no mutation in genital skin fibroblasts. These results correspond was found after screening all the exons and their with the observation that binding was not measurable flanking intronic sequences with PCR-SSCP. All three in cytosol from the patient's genital skin fibroblasts. In patients were clinically well diagnosed. AR protein was isolated from genital skin fibroblasts, obtained from these subjects, and molecular mass was established after SDS-PAGE and Western blotting. In all cases the AR protein migrated as a normal 110-112 kDa doublet. Receptor characteristics were further studied by Scatchard analysis, from which it became clear that the AR of the efficiency of reinitiation may be governed by the these three patients displayed normal K The cytosine-to-adenine transition at codon 564, converting an alanine residue into an aspartic acid residue in the first zinc finger of the D N A binding domain of the AR, resulted in a complete AIS phenotype. The phenotype was caused by the defective D N A binding and transactivation capacities of the mutant receptor. Although the correct 3-D structure of this mutant AR is not available, the effect of the mutation can be deduced from the 3-D structure of the glucocorticoid D N A binding domain [14] . Cysteine 560, histidine 561, and tyrosine 562 are involved either in specific or aspecific contacts with the phosphate backbone of the D NA (Fig. 4) . The amino acid substitution in the mutant receptor might interfere with these contacts, resulting in defective D N A binding.
In the AR gene of three subjects with an AIS-like phenotype, no mutations were found with PCR-SSCP. Although receptor characteristics appear to be normal, the presence of a mutation, not influencing ligand binding, cannot be excluded. There is still a possibility that some mutations are being missed by the screening procedure we used. However, in our laboratory so far all mutations which were previously found by direct sequencing, could be confirmed by PCR-SSC P afterwards. AR proteins appeared as normal 1 1 0 -112 kDa doublets in genital skin fibroblasts and furthermore normal K d and B max values were measured. This does not rule out abnormal protein expression in other target tissues. Another explanation for the androgen resistance syndrome might be the presence of a mutation in a gene, encoding a factor specifically involved in transcriptional regulation of AR target genes.
